Tanaya Bhowmick

Tanaya Bhowmick

Auto-generated profile, based on publicly available information

Tanaya Bhowmick

UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
RWRichard G. Wunderink
Richard G. Wunderink
EGEvangelos J. Giamarellos-Bourboulis
Evangelos J. Giamarellos-Bourboulis
GRGalia Rahav
Galia Rahav
AMAmy J. Mathers
Amy J. Mathers
MBMatteo Bassetti
Matteo Bassetti
KKKeith S. Kaye
Keith S. Kaye
Introduction Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations. A Phase 3, multinational, open-label, randomized controlled trial (TANGO II) was conducted from 2014 to 2017 to evaluate the efficacy/safety of meropenem–vaborbactam monotherapy versus best available therapy (BAT) for CRE. Methods A total of 77 patients with confirmed/suspected CRE infection (bacteremia, hospital-acquired/ventilator-associated bacterial pneumonia, complicated intra-abdominal infection, complicated urinary tract infection/acute pyelonephritis) were randomized, and 47 with confirmed CRE infection formed the primary analysis population (microbiologic-CRE-modified intent-to-treat, mCRE-MITT). Eligible patients were randomized 2:1 to meropenem–vaborbactam (2 g/2 g over 3 h, q8h for 7–14 days) or BAT (mono/combination therapy with polymyxins, carbapenems, aminoglycosides, tigecycline; or ceftazidime-avibactam alone). Efficacy endpoints included clinical cure, Day-28 all-cause mortality, microbiologic cure, and overall success (clinical cure + microbiologic eradication). Safety endpoints included adverse events (AEs) and laboratory findings. Results Within the mCRE-MITT population, cure rates were 65.6% (21/32) and 33.3% (5/15) [95% confidence interval (CI) of difference, 3.3% to 61.3%; P = 0.03)] at End of Treatment and 59.4% (19/32) and 26.7% (4/15) (95% CI of difference, 4.6% to 60.8%; P = 0.02) at Test of Cure;.Day-28 all-cause mortality was 15.6% (5/32) and 33.3% (5/15) (95% CI of difference, − 44.7% to 9.3%) for meropenem–vaborbactam versus BAT, respectively. Treatment-related AEs and renal-related AEs were 24.0% (12/50) and 4.0% (2/50) for meropenem–vaborbactam versus 44.0% (11/25) and 24.0% (6/25) for BAT. Exploratory risk–benefit analyses of composite clinical failure or nephrotoxicity favored meropenem–vaborbactam versus BAT (31.3% [10/32] versus 80.0% [12/15]; 95% CI of difference, − 74.6% to − 22.9%; P < 0.001). Conclusions Monotherapy with meropenem–vaborbactam for CRE infection was associated with increased clinical cure, decreased mortality, and reduced nephrotoxicity compared with BAT. Clinical Trials Registration NCT02168946. Funding The Medicines Company.

27 February 2018 in JAMA
Verified
Journal Article
Open access
PDF file
KKKeith S. Kaye
Keith S. Kaye
TBTanaya Bhowmick
Tanaya Bhowmick
SMSymeon Metallidis
Symeon Metallidis
SBSusan C. Bleasdale
Susan C. Bleasdale
OSOlexiy S. Sagan
Olexiy S. Sagan
EGEvangelos J. Giamarellos-Bourboulis
Evangelos J. Giamarellos-Bourboulis
Spread of beta-lactamase enzymes among gram-negative pathogens threatens the usefulness of many beta-lactam antibiotics and has resulted in greater reliance on carbapenems.1,2 Dissemination of carbapenemases (eg, Klebsiella pneumoniae carbapenemase) in Enterobacteriaceae worldwide is identified as an urgent threat by the Centers for Disease Control and Prevention, and the World Health Organization has identified development of new agents as a critical need.3-5 Quiz Ref ID Infections due to carbapenem-resistant Enterobacteriaceae are most often urinary tract infections (UTIs), including acute pyelonephritis,6 and are usually health care–associated.7,8 Mortality attributable to carbapenem-resistant Enterobacteriaceae infections is 20% to 54.3%6,9-11 and reflects the need for better treatment options.

21 November 2023 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
VPVirginia M. Pierce
Virginia M. Pierce
TBTanaya Bhowmick
Tanaya Bhowmick
PSPatricia J. Simner
Patricia J. Simner
Antimicrobial susceptibility test and report guidelines are an important tool for antimicrobial stewardship programs. Since 1972, Tables 1 within the Clinical and Laboratory Standards Institute (CLSI) M100 document have provided a general framework upon which clinical microbiologists and antimicrobial stewardship teams can build algorithms for susceptibility testing and reporting that meet the specific needs of their institution. Many changes were made to Tables 1 in M100-Ed33 to modernize the content to reflect the landscape of current clinical practice, including the growing armamentarium of antimicrobial agents, the emergence of new mechanisms of antimicrobial resistance, the increasing prevalence of infections caused by multidrug-resistant organisms, and updated consensus recommendations for first-choice and alternative agents for treatment. With these items in mind, the CLSI Table 1 ad hoc working group revised Tables 1 with the ultimate goal of supporting institutions in the creation of individualized test and report strategies that support local antimicrobial stewardship program initiatives. These strategies are built on the concepts of selective and cascade reporting. This minireview introduces the concept of CLSI M100-Ed33 Tables 1, describes the changes to Tables 1 introduced in 2023, and provides clinical vignettes that demonstrate how Tables 1 can be used in various scenarios to devise antimicrobial susceptibility test and report strategies.

5 October 2020 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
TBTanaya Bhowmick
Tanaya Bhowmick
MWMelvin P. Weinstein
Melvin P. Weinstein
Vaborbactam is a novel boron-based beta-lactamase inhibitor developed to be effective against Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria. This enzyme is a key driver in the global spread of β-lactam resistance among carbapenem-resistant Enterobacterales. Alone, vaborbactam has no antibacterial activity; however, the combination of meropenem-vaborbactam has enhanced activity against gram-negative organisms, particularly Enterobacterales with class A and C carbapenemases. Multiple in vitro studies evaluating isolates from various geographic regions, and over different time periods, have demonstrated the high potency of meropenem-vaborbactam against organisms containing KPC2 and KPC3. However, meropenem-vaborbactam does not have activity against OXA-48 or metallo-beta lactamases. This review covers the in vitro studies of meropenem-vaborbactam performed to date, which evaluated both large cohorts of clinical isolates and engineered isolates, to determine efficacy in various settings, including the presence of porin mutations and efflux pump upregulation.

1 April 2013 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
TBT. Bhowmick
T. Bhowmick
SMS. Mirrett
S. Mirrett
LRL. B. Reller
L. B. Reller
CPC. Price
C. Price
CQC. Qi
C. Qi
TKT. J. Kirn
T. J. Kirn
Staphylococci are a frequent cause of bloodstream infections (BSIs). Appropriate antibiotic treatment for BSIs may be delayed because conventional laboratory testing methods take 48 to 72 h to identify and characterize isolates from positive blood cultures. We evaluated a novel assay based on bacteriophage amplification that identifies Staphylococcus aureus and differentiates between methicillin-susceptible and methicillin-resistant S. aureus (MSSA and MRSA, respectively) in samples taken directly from signal-positive Bactec blood culture bottles within 24 h of positive signal, with results available within 5 h. The performance of the MicroPhage KeyPath MRSA/MSSA blood culture test was compared to conventional identification and susceptibility testing methods. At four sites, we collectively tested a total of 1,165 specimens, of which 1,116 were included in our analysis. Compared to standard methods, the KeyPath MRSA/MSSA blood culture test demonstrated a sensitivity, specificity, positive predictive value, and negative predictive value of 91.8%, 98.3%, 96.3%, and 96.1%, respectively, for correctly identifying S. aureus. Of those correctly identified as S. aureus (n = 334), 99.1% were correctly categorized as either MSSA or MRSA. Analysis of a subset of the data revealed that the KeyPath MRSA/MSSA blood culture test delivered results a median of 30 h sooner than conventional methods (a median of 46.9 h versus a median of 16.9 h). Although the sensitivity of the test in detecting S. aureus-positive samples is not high, its accuracy in determining methicillin resistance and susceptibility among positives is very high. These characteristics may enable earlier implementation of appropriate antibiotic treatment for many S. aureus BSI patients.

1 April 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
SAShaili Adani
Shaili Adani
TBTanaya Bhowmick
Tanaya Bhowmick
MWMelvin P. Weinstein
Melvin P. Weinstein
NNNavaneeth Narayanan
Navaneeth Narayanan
Methicillin-resistant Staphylococcus aureus (MRSA) is a leading cause of bacteremia and is associated with significant morbidity and mortality. Prior studies evaluating the association of vancomycin MICs with clinical outcomes in patients with MRSA bacteremia have been inconsistent. This study evaluated the association between vancomycin MICs and 30-day in-hospital mortality rates for patients with MRSA bacteremia. This was a retrospective cohort study of patients with MRSA bacteremia treated with vancomycin for ≥72 h from January 2013 to August 2016. Vancomycin MICs were determined by broth microdilution via automated susceptibility testing methods. Study groups consisted of patients with MRSA isolates that had vancomycin MICs of <2 μg/ml and those with vancomycin MICs of 2 μg/ml. Covariates included demographics, severity of illness, comorbidities, intensive-care unit (ICU) admission, infectious disease consultation, infectious sources, and hospital onset of bacteremia. The primary outcome was 30-day in-hospital mortality. Secondary outcomes included the duration of bacteremia, persistent bacteremia for ≥7 days, recurrence within 30 days, change to alternative antibiotic therapy, and length of hospital stay. Multivariate logistic regression models were analyzed to control for potential confounding variables. A total of 166 patients were included for analysis: 91 patients with vancomycin MICs of <2 μg/ml and 75 patients with vancomycin MICs of 2 μg/ml. In the multivariate logistic regression model, a vancomycin MIC of 2 μg/ml, compared to a MIC of <2 μg/ml, was not significantly associated with 30-day in-hospital mortality after adjustment for confounders. Additionally, all secondary outcomes were not statistically significantly different between study groups. In patients with MRSA bacteremia treated with vancomycin, the vancomycin MIC was not associated with differences in clinical outcomes.